2014
A Marginal Benefit Approach for Vaccinating Influenza “Superspreaders”
Skene KJ, Paltiel AD, Shim E, Galvani AP. A Marginal Benefit Approach for Vaccinating Influenza “Superspreaders”. Medical Decision Making 2014, 34: 536-549. PMID: 24740238, PMCID: PMC4209160, DOI: 10.1177/0272989x14523502.Peer-Reviewed Original ResearchConceptsHerd immunity thresholdSeasonal influenza epidemicsVaccination coverageSeasonal influenzaVaccination strategiesEpidemiological findingsImmunity thresholdHerd immunityInfluenza epidemicsVaccination changesPotential superspreadersSimplified transmission modelVaccinationTarget populationIntervention designEpidemicInfluenzaInterventionTransmission model
2011
Dengue vector control strategies in an urban setting: an economic modelling assessment
Luz PM, Vanni T, Medlock J, Paltiel AD, Galvani AP. Dengue vector control strategies in an urban setting: an economic modelling assessment. The Lancet 2011, 377: 1673-1680. PMID: 21546076, PMCID: PMC3409589, DOI: 10.1016/s0140-6736(11)60246-8.Peer-Reviewed Original ResearchConceptsCost-effectiveness ratioHerd immunityAdult controlsDengue burdenIncremental cost-effectiveness ratioDengue transmissionCost-effective interventionResource-constrained countriesProbabilistic sensitivity analysesCost-effectiveness analysisIncidence of dengueFuture dengue epidemicsImmunological effectsHealth burdenRisk of dengueVector control policiesDengue epidemicsImmunityVector control strategiesBurdenDengueAdult mosquitoesInterventionEpidemicYears
2009
Cost-Effectiveness of Preventing Loss to Follow-up in HIV Treatment Programs: A Côte d'Ivoire Appraisal
Losina E, Touré H, Uhler LM, Anglaret X, Paltiel AD, Balestre E, Walensky RP, Messou E, Weinstein MC, Dabis F, Freedberg KA, AIDS F, investigators A. Cost-Effectiveness of Preventing Loss to Follow-up in HIV Treatment Programs: A Côte d'Ivoire Appraisal. PLOS Medicine 2009, 6: e1000173. PMID: 19859538, PMCID: PMC2762030, DOI: 10.1371/journal.pmed.1000173.Peer-Reviewed Original ResearchConceptsHIV treatment programsResource-limited settingsPerson/yearART initiationAIDS Complications-International modelTreatment programWorld Health Organization criteriaAntiretroviral therapy initiationLTFU ratesHIV careTherapy initiationCumulative incidenceClinical benefitOrganization criteriaClinical impactLTFUPayer perspectiveCost of interventionInternational criteriaLife expectancyEfficacyInterventionPreventing LossCareSurvival loss
2006
Cost-Effectiveness of an Intervention to Improve Adherence to Antiretroviral Therapy in HIV-Infected Patients
Freedberg KA, Hirschhorn LR, Schackman BR, Wolf LL, Martin LA, Weinstein MC, Goldin S, Paltiel AD, Katz C, Goldie SJ, Losina E. Cost-Effectiveness of an Intervention to Improve Adherence to Antiretroviral Therapy in HIV-Infected Patients. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2006, 43: s113-s118. PMID: 17133193, DOI: 10.1097/01.qai.0000248334.52072.25.Peer-Reviewed Original ResearchConceptsStandard careNursing interventionsClinical trialsLong-term survival benefitIncremental cost-effectiveness ratioCohort of HIVQuality-adjusted life yearsLifetime medical costsCost-effectiveness ratioVirologic suppressionAntiretroviral therapyViral suppressionAntiretroviral medicationsHIV diseaseSurvival benefitClinical outcomesAdherence interventionsAntiretroviral adherenceMedical costsLife yearsModest effectivenessPatientsInterventionAdherenceHIV